AI Automated Translation.

Font Size

Share

Dongkook Pharmaceutical Q3 revenue at 258.7 billion won, up 14% year-on-year… "Full-fledged results from overseas cosmetics business"

Dongkook Pharmaceutical Q3 revenue at 258.7 billion won, up 14% year-on-year… "Full-fledged results from overseas cosmetics business"

Q3 operating profit at 23.8 billion won, down 4.1% year-on-year… Outlook for first-ever annual revenue milestone of 1 trillion won

Exterior view of Dongkook Pharmaceutical headquarters /Photo=Dongkook Pharmaceutical
Exterior view of Dongkook Pharmaceutical headquarters /Photo=Dongkook Pharmaceutical

Dongkook Pharmaceutical disclosed through its quarterly report that its consolidated operating profit for the third quarter was 23.8 billion won, a decrease of 4.1% compared to the same period last year. During the same period, revenue increased by 14.0% to 258.7 billion won, while net income decreased by 36.1% to 14.3 billion won.

The cumulative consolidated operating profit for the first three quarters was 77.2 billion won, an increase of 6.9% compared to the same period last year, and revenue rose by 12.4% to 768.6 billion won. Net income decreased by 0.9% to 57.8 billion won. Consequently, it is expected that Dongkook Pharmaceutical's annual revenue this year will surpass 1 trillion won for the first time.

On a standalone basis, Dongkook Pharmaceutical's third-quarter operating profit increased by 23.3% year-on-year to 23.1 billion won, and revenue rose by 18.3% to 222.1 billion won. Net income decreased by 33.3% to 10.9 billion won. On a cumulative basis, revenue was 658.6 billion won and operating profit was 70.9 billion won, representing increases of 17.2% and 23.3%, respectively, compared to the same period last year. Net income increased by 9.9% to 51.7 billion won.

Dongkook Pharmaceutical explained that its consolidated revenue growth rate was lower than on a standalone basis due to sluggish sales at its subsidiary, Dongguk Life Science.

A company official stated, "The results of Dongguk Life Science reflect the decline in revenue from the Medical Equipment (ME) business segment caused by deteriorating conditions in the diagnostic equipment market, as well as decreases in revenue and profit arising from portfolio restructuring, including the relocation of a production plant for contrast agents (raw materials and finished products) for global exports." The official added, "Once this business structure reorganization of Dongguk Life Science is completed, management efficiency and profitability are expected to improve."

Looking solely at Dongkook Pharmaceutical's own performance, it was explained that the overseas business division of the Health & Beauty Business Headquarters has begun to show substantial results, maintaining a high growth rate. "Madeca Cream" surpassed 100 million units sold as of the cumulative sales through September this year since its launch. The cumulative revenue for the "Centellian24" brand reached 1 trillion won from 2015 to 2024.

A company official said, "We are rapidly expanding distribution and brand touchpoints in major global markets such as North America, Europe, Japan, and Southeast Asia." The official added, "The revenue growth rate of the Healthcare Business Headquarters was 30.9% compared to the same period last year, with cosmetics (including beauty devices and exports) growing by 40%."

The official further stated, "We aim to leap forward as a global Health & Beauty company by expanding our overseas revenue share and informing global consumers of Dongkook Pharmaceutical's technological capabilities and brand competitiveness."

In the pharmaceutical export sector, performance outlooks are bright due to factors such as signing supply and license agreements for the improved new drug compound for benign prostatic hyperplasia, "Uresco," in the Latin America region. Dongkook Pharmaceutical plans to sequentially commercialize products such as the prostate cancer treatment "Lorelin" (1-month and 3-month formulations) through pipelines (drug candidates) utilizing its proprietary DDS (Drug Delivery System) platform technologies, including microspheres, and open innovation with relevant institutional investors. The company also intends to continue its growth by developing and launching new pharmaceutical products such as obesity treatments, acromegaly treatments, and immunosuppressants.

"This article was translated using AI and may differ slightly from the original."